At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
AG-013736drug
Likely dose
AG-013736 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating AG-013736 for Thyroid Neoplasms. Completed, enrolled 52 participants across 26 sites in 9 countries.
Detailed Summary
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Neoplasms
CountriesCanada, China, Czechia, India, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartDec 2006
Primary CompletionSep 2012
TodayJul 2026
First PostedOct 18, 2006
Enrollment StartDec 1, 2006
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 19.7 years ago
Interventions
AG-013736drug
AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity